Shannon Rourke Devens
Corporate Officer/Principal bij SURFACE ONCOLOGY, INC.
Actieve functies van Shannon Rourke Devens
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| SURFACE ONCOLOGY, INC. | Corporate Officer/Principal | 15-12-2021 | - |
| Hoofd Techniek/Wetenschap/O&O | 01-02-2018 | 15-12-2021 |
Loopbaan van Shannon Rourke Devens
Eerdere bekende functies van Shannon Rourke Devens
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| INFINITY PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
Opleiding van Shannon Rourke Devens
| Northeastern University | Graduate Degree |
| University of Colorado Boulder | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 5 |
Operationeel
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Graduate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
